Methods of suppressing fibrosis and fibrocyte formation

Details Methods of suppressing fibrosis and fibrocyte formation Methods of suppressing fibrosis and fibrocyte formation

2005-06-22

2010-02-23

Landsman, Robert (Department: 1646)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Hormone or other secreted growth regulatory factor,...

C512S002000, C530S350000

Reexamination Certificate

active

07666432

ABSTRACT:
The present invention relates to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress the differentiation of monocytes into fibrocytes. Methods and compositions for suppressing differentiation of monocytes into fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate monocyte differentiation into fibrocytes and to detect monocyte defects. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.

REFERENCES:
patent: 4233969 (1980-11-01), Lock et al.
patent: 4782014 (1988-11-01), Serban et al.
patent: 5092876 (1992-03-01), Dhawan et al.
patent: 5591709 (1997-01-01), Lindenbaum
patent: 5654186 (1997-08-01), Cerami et al.
patent: 5698589 (1997-12-01), Allen
patent: 5804446 (1998-09-01), Cerami et al.
patent: 5846796 (1998-12-01), Cerami et al.
patent: 6037458 (2000-03-01), Hirai et al.
patent: 6054121 (2000-04-01), Cerami et al.
patent: 6126918 (2000-10-01), Pepys et al.
patent: 6174526 (2001-01-01), Cerami et al.
patent: 6365570 (2002-04-01), Van Kessel et al.
patent: 6406698 (2002-06-01), Svehag et al.
patent: 6537811 (2003-03-01), Freier
patent: 6600019 (2003-07-01), Prayaga et al.
patent: 6872541 (2005-03-01), Mills
patent: 2002/0058284 (2002-05-01), Winkel
patent: 2003/0003567 (2003-01-01), Barber et al.
patent: 2003/0022245 (2003-01-01), Mills
patent: 2004/0068095 (2004-04-01), Shimkets et al.
patent: 2005/0238620 (2005-10-01), Gomer et al.
patent: 9941285 (1999-08-01), None
patent: 0174300 (2001-10-01), None
patent: 03031572 (2003-04-01), None
patent: 03097104 (2003-11-01), None
patent: 2004058292 (2003-12-01), None
patent: 2004059318 (2003-12-01), None
patent: 2004016750 (2004-02-01), None
patent: 2004059318 (2004-07-01), None
patent: 2005110474 (2005-11-01), None
patent: 2005115452 (2005-12-01), None
patent: 2006002438 (2006-01-01), None
F.C. de Beer et al., “Fibronectin and C4-Binding Protein are Selectively Bound by Aggregated Amyloid Component”, the Rockefeller University Press, vol. 154, pp. 1134-1149, Oct. 1981.
Lawrence A. Potempa et al., “Effect of Divalent Metal Ions and pH Upon the Binding Reactivity of Human Serum Amyloid P Component, a C-Reactive Protein Homologue, for Zymosan”, The Journal of Biological Chemistry, vol. 260, pp. 12142-12147, Oct. 5, 1985.
Terry W. Du Clos, “C-Reactive Protein Reacts With the U1 Small Nuclear Ribonucleoprotein”, The Journal of Immunology, vol. 143, pp. 2553-2559, Oct. 15, 1989.
Marilyn R. Brown et al., “Receptor-Ligand Interactions Between Serum Amyloid P Component and Model Soluble Immune Complexes”, The Journal of Immunology, vol. 151, pp. 2087-2095, Aug. 15, 1983.
Lorraine L. Marnell et al., “C- Reactive Protein Binds to FcγR1 in Transfected COS Cells”, The American Association of Immunologists, 9 Pgs., Feb. 22, 1995.
Annalisa D'Andrea et al., “Stimulatory and Inhibitory Effects of Interleukin (IL)-4 and IL-13 on the Production of Cytokines by Human Peripheral Blood Mononuclear Cells: Priming for IL-12 and Tumor Necrosis Factor α Production”, The Rockefeller University Press, vol. 181, pp. 537-546, Feb. 1995.
Kamyar Zahedi, “Characterization of the Binding of Serum Amyloid P to Type IV Collagen”, The Journal of Biological Chemistry, vol. 271, No. 25, pp. 14897-14902, Jun. 21, 1996.
Marc Daëron, “Fc Receptor Biology”, www.arjournals.annualreviews.org , pp. 203-234, 1997.
Kamyar Zahedi, “Characterization of the Binding of Serum Amyloid P to Laminin”, The Journal of Biological Chemistry, vol. 272, No. 4, pp. 2143-2148, Jan. 24, 1997.
Carla J.C. de Haas et al., “A Synthetic Lipopolysaccharide-Binding Peptide Based on Amino Acids 27-39 of Serum Amyloid P Component Inhibits Lipopolysaccharide-Induced Responses in Human Blood”, The Journal of Immunology, pp. 3607-3615, 1998.
Dwaipayan Bharadwaj et al., “The Major Receptor for C-Reactive Protein on Leukocytes Is Fcγ Receptor II”, The Journal of Experimental Medicine, vol. 190 No. 4, pp. 585-590, Aug. 16, 1999.
M.C.M. Bickerstaff et al., “Serum Amyloid P Component Controls Chromatin Degration and Prevents Antinuclear Autoimmunity”, Nature Medicine, vol. 5, No. 6, pp. 694-697, Jun. 1999.
Fayyaz S. Sutterwala et al., “The Taming of IL-12 Suppressing the production of Proinflammatory Cytokines”, Journal of Leukocyte Biology, vol. 65, pp. 543-551, May 1999.
Richard F. Mortensen et al., “Regulation of Phagocytic Leukocyte Activities by C-reactive Protein”, Journal of Leukocyte Biology, vol. 67, pp. 495-500, Apr. 2000.
Mary-Pat Stein et al., “C-reactive Protein Binding to FcγRIIa on Human Monocytes and Neutrophils is Allele-Specific”, The Journal of Clinical Investigation, vol. 105, pp. 369-376, Feb. 2000.
Dwaipayan Bharadwaj et al., “Serum Amyloid P Component Binds to Fcγ Receptors and Opsonizes Particles for Phagocytosis”, The Journal of Immunology, vol. 166, pp. 6735-6741, 2001.
Eirikur Saeland et al., “Human C-reactive Protein Does not Bind to FcγRIIa on Phagocytic Cells”, The Journal of Clinical Investigation, vol. 107 No. 5, pp. 641-643, Mar. 2001.
Carolyn Mold et al., “Serum Amyloid P Component and C-Reactive Protein Mediate Phagocytosis Through Murine FcγRs”, The Journal of Immunology, vol. 166, pp. 1200-1205, 2001.
Katherine B. Bodman-Smith et al., “C-Reactive Protein-Mediated Phagocytosis and Phospholipase D Signalling Through the High-Affinity Receptor for Immunoglobulin G (FcγRI)”, The Journal of Immunology, vol. 107 No. 2, pp. 252-260, Oct. 2002.
Matthias Schmidt et al., “Identification of Circulating Fibrocytes as Precursors of Bronchial Myofibroblasts in Asthma”, The Journal of Immunology, vol. 170, pp. 380-389, Apr. 22, 2003.
Liju Yang et al., “Peripheral Blood Fibrocytes From Burn Patients: Identification and Quantification of Fibrocytes in Adherent Cells Cultured From Peripheral Blood Mononuclear Cells”, Laboratory Investigation, vol. 82, No. 9, pp. 1183-1192, Apr. 15, 2002.
Thomas A. Wynn, “IL-13 Effector Functions”, www.arjoumals.annualreviews.org , pp. 425-456, 2003.
Roderick J. Philips et al., “Circulating Fibrocytes Traffic to the Lungs in Response to CXCL 12 and Mediate Fibrosis”, The Journal of Clinical Investigation, vol. 114, No. 3, pp. 438-446, Aug. 2004.
Bethany B. Moore et al., “CCR2-Mediated Recruitment of Fibrocytes to the Alveolar Space After Fibrotic Injury”, American journal of Pathology, vol. 166, No. 3, pp. 675-684, Mar. 2005.
Luca Mori et al., “Fibrocytes Contribute to the Myofibroblast Population in Wounded Skin and Originate From the Bone Marrow”, www.sciencedirect.com , pp. 81-90, Aug. 10, 2004.
Liju Yang, PhD et al., “Identification of Fibrocytes in Postburn Hypertrophic Scar”, Wound Repair and Regeneration, vol. 13, No. 4, pp. 398-404, Jan. 17, 2005.
Riichiro Abe et al., “Peripheral Blood Fibrocytes: Differentaion Pathway and Migration to Wound Sites”, The Journal of Immunology, Vol. 166, pp. 7556-7562, 2001.
Jason Chesney et al., “The Peripheral Blood Fibrocyte is a Potent Antigen-Presenting Cell Capable of Priming Naive T Cells in Situ”, Journal of Immunology, vol. 94, pp. 6307-6312, Jun. 1997.
Darrell Pilling et al., “Inhibition of Fibrocyte Differentation by Serum Amyloid P1”, The Journal of Immunology, vol. 171, pp. 5537-5546, 2003.
C.N. Metz, “Fibrocytes: A unique Cell Population Implicated in Wound Healing”, Cell. Mol. Life Sci., vol. 60, pp. 1342-1350, Jan. 16, 20

Affiliated with

Also associated with

Rating

Methods of suppressing fibrosis and fibrocyte formation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of suppressing fibrosis and fibrocyte formation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of suppressing fibrosis and fibrocyte formation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4221286